Creo Medical Group plc

("Creo" the "Company" or the "Group")

Microwave Lung Ablation Update

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces progress with its MicroBlate Flex device.

Professor Pallav Shah and Dr Christopher Orton, of the Royal Brompton Hospital, have become the first specialists in the world to perform a robotic guided microwave ablation of lung tissue in the same sitting as a diagnostic procedure. Creo's MicroBlate Flex device was used to perform the procedure.

In a recent announcement, Professor Shah and his team reported that microwave ablation was used to ablate a 27mm cancerous nodule in a patient's lung. The procedure took place at the Royal Brompton Hospital in London and is reported to have taken 3 minutes. 

Dr Orton commented: "The potential to combine the diagnosis, staging and treatment of lung cancer in one procedure offers significant benefit to patients." 

Link: https://www.rbhh-specialistcare.co.uk/news/ion-robot-lung-tumour

Craig Gulliford, Chief Executive Officer of Creo, said: "Creo has been pioneering minimally invasive surgical endoscopy for pre-cancer and cancer patients for years, and implementing our technology into robotic application is a key goal for us as the adoption of this technology continues to grow exponentially.

"We are incredibly proud that our MicroBlate Flex technology has been able to make this world-first possible. The potential for these technologies to combine precise robotically guided lung cancer diagnosis with the ablation of cancerous tissue in one session is transformational. Not only could this dramatically improve outcomes for lung cancer patients, but it has the potential to do away with long and worrying delays between diagnosis and treatment. This is the beginning of an exciting program and the team have done a terrific job in reaching this point."

Enquiries:

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com